← Back to Screener
Context Therapeutics Inc. Common Stock (CNTX)
Price$1.75
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)48.32%
Price vs S&P 500 (4W)-26.46%
VGM Score50.58
Market Capitalization$160.79M
All Metrics
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)0.40x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.36
Price vs S&P 500 (YTD)10.89%
EPS (TTM)$-0.42
10-Day Avg Trading Volume0.86M
EPS Excl Extra (TTM)$-0.42
EPS (Annual)$-0.38
ROI (Annual)-59.73%
Cash / Share (Quarterly)$0.59
ROA (Last FY)-52.74%
EBITD / Share (TTM)$-0.46
ROE (5Y Avg)-70.80%
Cash Flow / Share (Annual)$-0.29
P/B Ratio3.08x
P/B Ratio (Quarterly)4.61x
Net Income / Employee (Annual)$-2,408,200
Net Interest Coverage (TTM)-208.20x
ROA (TTM)-54.78%
EPS Incl Extra (Annual)$-0.38
Current Ratio (Annual)8.52x
Quick Ratio (Quarterly)8.38x
3-Month Avg Trading Volume1.03M
52-Week Price Return217.26%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.15
52-Week High$3.62
EPS Excl Extra (Annual)$-0.38
26-Week Price Return56.25%
Quick Ratio (Annual)8.25x
13-Week Price Return-38.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.96x
Enterprise Value$106.26M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.72
3-Month Return Std Dev97.47%
Net Income / Employee (TTM)$-2,681,800
ROE (Last FY)-59.73%
EPS Basic Excl Extra (Annual)$-0.38
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.42
ROI (TTM)-59.95%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.18
Price vs S&P 500 (52W)192.89%
Year-to-Date Return19.05%
5-Day Price Return-37.28%
EPS Normalized (Annual)$-0.38
ROA (5Y Avg)-57.73%
Month-to-Date Return-38.60%
Cash Flow / Share (TTM)$-1.30
EBITD / Share (Annual)$-0.42
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-70.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.42
P/TBV (Quarterly)0.75x
P/B Ratio (Annual)2.23x
Book Value / Share (Annual)$0.66
Price vs S&P 500 (13W)-47.07%
Beta1.73x
Revenue / Share (TTM)$0.00
ROE (TTM)-59.95%
52-Week Low$0.54
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.09est. -0.12
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.19
4.19
4.19
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTXContext Therapeutics Inc. Common Stock | — | — | C | $1.75 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Context Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies for solid tumors, with an initial focus on hormone-dependent cancers in women, including breast, ovarian, and endometrial cancer. Its lead program, CTIM-76, is a bispecific antibody that redirects T-cells to attack cancer cells expressing CLDN6, combining immune activation with tumor-specific targeting. The company aims to deliver efficacy while minimizing off-target effects through this precision approach.